Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants

Launched by NICOLAI JACOB WEWER ALBRECHTSEN · Apr 3, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how increasing levels of a hormone called glucagon affect the way our bodies process sugar. Glucagon plays a key role in controlling blood sugar levels, and researchers want to see how its infusion impacts healthy individuals. Participants will take part in a single study day where they will have some initial blood tests, followed by a three-hour infusion of glucagon that will be gradually increased during the session.

To join this study, participants need to be between 25 and 70 years old and have a healthy body weight (a Body Mass Index of 25 or less). They should not have diabetes, be pregnant or breastfeeding, or have certain health conditions like liver or kidney disease. Throughout the study, participants can expect to provide blood samples to help researchers gather information on how glucagon affects their metabolism. It's important to note that this trial is not yet recruiting participants, so those interested will need to wait until it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Capable of understanding the participant information and signing the consent form
• • Between 25 and 70 years of age at the time of screening
• • Body mass index (BMI) ≤ 25 kg/m2 at the time of screening
• Exclusion Criteria:
• • Enrolment in other research projects that might interfere with the study
• • Diabetes diagnosis (type 1 and 2)
• • Pregnancy or breastfeeding
• • Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
• • Impaired liver function defined as either alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥ 2 times normal values
• • Kidney disease defined as serum creatinine levels ≥ 126 μmol/L for male and ≥ 111 μmol/L for female
• • Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic
• • Active or recent malignant disease
• • Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement
• • Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol